Scottish Medicines Consortium (SMC) recommended the use of inotuzumab ozogamicin
The Scottish Medicines Consortium (SMC) issues restricted recommendation for use of inotuzumab ozogamicin in the treatment of adults with relapsed/refractory acute lymphoblastic leukaemia (ALL) in Scotland.